Coronavirus disease 2019 (COVID-19): Current situation and therapeutic options

Coronaviruses ◽  
2020 ◽  
Vol 01 ◽  
Author(s):  
Veer Singh ◽  
Vishal Mishra
Keyword(s):  
Monoclonal Antibodies ◽  
Transmission Rate ◽  
Therapeutic Options ◽  
World Health ◽  
Plasma Therapy ◽  
The World ◽  
Working Together ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Effective Drugs

Abstract:: Coronavirus disease 2019 (COVID-19) is defined an illness caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). COVID-19 was first reported in the Wuhan, China in late December, 2019. World Health Organization (WHO) declared COVID-19 a global emergency on March 11, 2020. COVID-19 was rapidly transmitted and caused infection in 21,294,845 people and 761,779 deaths in more than 213 countries worldwide till August 16, 2020. United States of America (USA), Brazil, India, Russia Federation, Peru, Mexico, Colombia Spain, France, Italy, Germany, and United Kingdom (UK) stand top COVID-19 affected countries in the world. The high transmission rate of COVID-19 was might be due to large viral incubation time (2-14 days) and some modifications in the spike glycoprotein. Currently, effective drugs or vaccines are not developed for the treatment of novel coronavirus. However, few antibiotics like hydroxychloroquine and remdesivir have been currently used for the treatment of COVID-19 infection. Several collaboratives are working together for developing an effective and safe vaccine against COVID-19 and few vaccines are under clinical trial. Scientists are also working on plasma therapy and monoclonal antibodies. Nowadays, plasma therapy is considered as the most effective treatment against COVID-19 and some promising results have been achieved. This review focuses on the several therapeutic options for COVID-19 such as antiviral drugs, vaccines, plasma therapy and monoclonal antibodies. This review also covers the current situations of COVID-19 in the world. This review is about COVID-19, which will be beneficial to researchers for the development of potential treatment against COVID-19.

scholarly journals Forecasting COVID-19 Transmission in India Using Deep Learning Models

2020 ◽  
Vol 10 (2) ◽  
pp. 2044-2055
Keyword(s):  
Transmission Rate ◽  
World Health ◽  
Similar Data ◽  
Slowing Down ◽  
Short Period ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Susceptible Populations ◽  
Near Future

In the past 6 months, the world has come to a standstill due to an escalation in the number of cases of COVID-19. COVID-19 is an infectious disease that was formerly called as 2019-nCoV or the novel Coronavirus 2019. COVID-19 first originated in Wuhan, China, in late December 2019, and subsequently, the World Health Organization declared it as a pandemic on 11th March, 2020. Lack of preparedness for the COVID-19 pandemic has put colossal stress on the healthcare systems of the world’s largest economies. In a short period, the disease has spread to an unexpected number of people due to its high transmission rate and doesn’t show a sign of slowing down in the near future. Estimating the rising number of cases via predictive modeling can help gauge the quantity of various medical amenities required for the treatment of patients as well as protective apparatus for essential workers and susceptible populations. In this paper, we have performed time series forecasting on the publicly available COVID-19 datasets of India using RNNs with LSTM and GRU. Additionally, we also employ the final models for analyzing similar data from different countries.

scholarly journals Convalescent plasma therapy for COVID-19: a review of old therapy against new disease

2020 ◽  
Vol 9 (12) ◽  
pp. 1909
Author(s):  
Utshav Chapagain ◽  
Gajendra Prasad Raunair ◽  
Kumud Chapagain ◽  
Rakesh Verma
Keyword(s):  
World Health ◽  
Cochrane Library ◽  
The Novel ◽  
Plasma Therapy ◽  
Investigational Treatment ◽  
The World ◽  
To Come ◽  
Novel Coronavirus ◽  
Health Organization ◽  
The Impact

Currently, novel coronavirus disease 2019 (COVID-19) is a big threat to global health which has revived the potential beneficial effect of ancient convalescent plasma therapy (CPT). This review was conducted to evaluate the effectiveness and adverse drug reactions associated with convalescent plasma therapy in COVID-19 patients, based on articles available to date. PubMed, Google Scholar, Cochrane library, and Hinari databases were searched until 15th September 2020. Every country across the globe today is encountered with a virus that has impacted millions of lives today and for generations to come. Nonetheless recommended antiviral drugs and vaccines are not evident and specified for novel coronavirus disease. This is now very well known that scientists and medical experts across the world are vigilant about recommending the use of CPT and call it an investigational treatment that may help in assisting recovery. The World health organization has perpetuated that there is not enough proof that plasma therapy works in treating those fighting the novel coronavirus. Therefore, convalescent plasma therapy is a feasible and immediate option for alleviating the impact of the disease. Comparing the effectiveness of convalescent plasma therapy with SARS-CoV, MERS-CoV, and COVID-19 would help in deriving proper outcomes for COVID-19 infected cases.

Current updates on COVID-19 - A review

2020 ◽  
Vol 10 (1) ◽  
pp. 1-8
Author(s):  
Ghotekar D S ◽  
Vishal N Kushare ◽  
Sagar V Ghotekar
Keyword(s):  
World Health Organization ◽  
Common Cold ◽  
Respiratory Diseases ◽  
Gastrointestinal Diseases ◽  
Hubei Province ◽  
World Health ◽  
The World ◽  
The Common ◽  
Novel Coronavirus ◽  
Health Organization

Coronaviruses are a family of viruses that cause illness such as respiratory diseases or gastrointestinal diseases. Respiratory diseases can range from the common cold to more severe diseases. A novel coronavirus outbreak was first documented in Wuhan, Hubei Province, China in December 2019. The World Health Organization (WHO) has declared the coronavirus disease 2019 (COVID-19) a pandemic. A global coordinated effort is needed to stop the further spread of the virus. A novel coronavirus (nCoV) is a new strain that has not been identified in humans previously. Once scientists determine exactly what coronavirus it is, they give it a name (as in the case of COVID-19, the virus causing it is SARS-CoV-2).

An approach to the understanding of the clinical-etiopathological aspect of COVID-19 (SARS-CoV-2)

2020 ◽  
Vol 11 (SPL1) ◽  
pp. 862-869
Author(s):  
Meena Kumari ◽  
Monika Agrawal ◽  
Rakesh Kumar Singh ◽  
Parameswarappa S Byadgi
Keyword(s):  
World Health ◽  
Apical Surface ◽  
Therapy Assessment ◽  
Differentiated Cells ◽  
The World ◽  
Polarized Epithelia ◽  
Well Differentiated ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Epidemiological Characteristics

Currently, the world is facing a health and socioeconomic crisis caused by the novel coronavirus disease COVID-19. On 11 March 2020, the World Health Organization (WHO) has declared this disease as a pandemic. The condition (COVID-19) is an infectious disorder triggered by a newly discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2. Most of the COVID-19 infected patients will experience mild to moderate respiratory symptoms and recover without any unique therapy. Assessment of the clinical and epidemiological characteristics of SARS-CoV-2 cases suggests the infected patients will not be contagious until the onset of severe symptoms and affects the other organs. Well-differentiated cells of apical airway epithelia communicating with ACE2 were promptly infected to SARS-CoV-2 virus. But the expression of ACE 2 in poorly differentiated epithelia facilitated SARS spike (S) protein-pseudo typed virus entry and it is replicated in polarized epithelia and especially exited via the apical surface. Limiting the transmission of COVID-19 infection & its prevention can be regarded as a hierarchy of controls. In this article, we briefly discuss the most recent advances in respect to aetiology, pathogenesis and clinical progression of the disease COVID-19.

Treatment Options in COVID-19: The Role of Bioavailable Antiviral Ribonucleoside Analog on NHC in vitro

2020 ◽  
Author(s):  
Lara Bittmann
Keyword(s):  
World Health Organization ◽  
Clinical Picture ◽  
Treatment Options ◽  
World Health ◽  
Wuhan City ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization

On December 31, 2019, WHO was informed of cases of pneumonia of unknown cause in Wuhan City, China. A novel coronavirus was identified as the cause by Chinese authorities on January 7, 2020 and was provisionally named "2019-nCoV". This new Coronavirus causes a clinical picture which has received now the name COVID-19. The virus has spread subsequently worldwide and was explained on the 11th of March, 2020 by the World Health Organization to the pandemic.

Critical Insight into the Attributes of Emerging Novel Coronavirus (COVID-19) in India and Across the World

Coronaviruses ◽  
2020 ◽  
Vol 1 (1) ◽  
pp. 49-56
Author(s):  
Gaurav M. Doshi ◽  
Hemen S. Ved ◽  
Ami P. Thakkar
Keyword(s):  
Review Article ◽  
World Health ◽  
Effective Vaccine ◽  
Human Contact ◽  
The World ◽  
Critical Insight ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Insight Into ◽  
Old Drugs

The World Health Organization (WHO) has recently announced the spread of novel coronavirus (nCoV) globally and has declared it a pandemic. The probable source of transmission of the virus, which is from animal to human and human to human contact, has been established. As per the statistics reported by the WHO on 11th April 2020, data has shown that more than sixteen lakh confirmed cases have been identified globally. The reported cases related to nCoV in India have been rising substantially. The review article discusses the characteristics of nCoV in detail with the probability of potentially effective old drugs that may inhibit the virus. The research may further emphasize and draw the attention of the world towards the development of an effective vaccine as well as alternative therapies. Moreover, the article will help to bridge the gap between the new researchers since it’s the current thrust area of research.

Outbreak of coronavirus disease 2019 (COVID-19) and its manifestation

Coronaviruses ◽  
2020 ◽  
Vol 01 ◽  
Author(s):  
Bikash Debnath ◽  
Waikhom Somraj Singh ◽  
Kuntal Manna
Keyword(s):  
Antiviral Drug ◽  
World Health ◽  
Family Welfare ◽  
Pregnant Mother ◽  
Vaccine Candidates ◽  
The World ◽  
Mode Of Transmission ◽  
Health Organization ◽  
Effective Drugs ◽  
Respiratory Droplets

: The coronavirus disease 2019 (COVID-19) first outbreak in Wuhan, China, and the infection is intense worldwide. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for COVID-19. The World Health Organization (WHO) confirmed total deaths had noted 4.20% globally (March 21, 2020). Between the intervals of four months (July 21, 2020), confirmed total deaths had recorded 4.17%, globally. In India, 909 confirmed cases and 19 deaths were reported by Health and Family Welfare, Government of India, March 28, 2020. Between the intervals of 123 days In India, 1638870 confirmed cases and 35684 deaths. COVID-19 can potentially spread from person to person through direct contact or respiratory droplets from coughing and sneezing. The most common symptoms are fever, dry cough, difficulty in breathing, and fatigue. A pregnant mother with COVID-19 has fewer chances to transfer this infection of her newborn babies. Children have less affected than an adult. A specific antiviral drug or vaccine has not been developed to cure the disease. Chloroquine, hydroxychloroquine, lopinavir, ritonavir, nafamostat, nitazoxanide, and remdesivir have effective drugs to treat COVID-19. Many vaccine candidates are under pre-clinical and clinical studies. In this review, we highlight the epidemiology, sign-symptoms, pathogenesis, mode of transmission, and effects of a pregnant mother with newborns, children, prevention, and drugs affective to COVID-19.

The Pandemic of Novel Coronavirus Disease 2019 (COVID-19): Need for an Immediate Action (Preprint)

2020 ◽  
Author(s):  
Mujib Ullah
Keyword(s):  
World Health Organization ◽  
Large Family ◽  
Current Treatment ◽  
World Health ◽  
New Disease ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization

UNSTRUCTURED Coronaviruses belong to a large family of viruses. Coronavirus also called COVID-19 is a new disease that has not been previously identified in humans. The World Health Organization has announced that COVID-19 is a pandemic. Currently there is no specific vaccine or treatment for COVID-19. Current treatment for COVID-19 is only supportive (treating the symptoms). There are no antiviral or vaccine options at this time. Therefore, it is time to bring collective efforts to treat or prevent a rapidly evolving pandemic of COVID-19.

scholarly journals Progression and Trends in Virus from Influenza A to COVID-19: An Overview of Recent Studies

Viruses ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1145
Author(s):  
Hakimeh Baghaei Daemi ◽  
Muhammad Fakhar-e-Alam Kulyar ◽  
Xinlin He ◽  
Chengfei Li ◽  
Morteza Karimpour ◽  
...  
Keyword(s):  
Influenza A ◽  
H1n1 Virus ◽  
World Health ◽  
H1n1 Pandemic ◽  
Global Pandemic ◽  
First Case ◽  
Influenza A H1n1 ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization

Influenza is a highly known contagious viral infection that has been responsible for the death of many people in history with pandemics. These pandemics have been occurring every 10 to 30 years in the last century. The most recent global pandemic prior to COVID-19 was the 2009 influenza A (H1N1) pandemic. A decade ago, the H1N1 virus caused 12,500 deaths in just 19 months globally. Now, again, the world has been challenged with another pandemic. Since December 2019, the first case of a novel coronavirus (COVID-19) infection was detected in Wuhan. This infection has risen rapidly throughout the world; even the World Health Organization (WHO) announced COVID-19 as a worldwide emergency to ensure human health and public safety. This review article aims to discuss important issues relating to COVID-19, including clinical, epidemiological, and pathological features of COVID-19 and recent progress in diagnosis and treatment approaches for the COVID-19 infection. We also highlight key similarities and differences between COVID-19 and influenza A to ensure the theoretical and practical details of COVID-19.

scholarly journals Importance of immunoglobulin therapy for COVID-19 patients with lymphocytopenia

2021 ◽  
Vol 45 (1) ◽  
Author(s):  
Heba K. Nabih
Keyword(s):  
Passive Immunization ◽  
Immunoglobulin Therapy ◽  
World Health ◽  
Clinical Feature ◽  
Main Body ◽  
Plasma Therapy ◽  
Rapid Spread ◽  
The World ◽  
Health Organization

Abstract Background The global coronavirus disease 2019 (COVID-19) was announced as pandemic by the World Health Organization (WHO). With the increased number of infected and dead victims daily all over the world, it becomes necessary to stop or overcome its rapid spread. Main body Although the production of vaccine or even specified effective anti-virus may take about six months to a year, intravenous immunoglobulin (IVIg) may be clinically used as a safe treatment to save and improve the quality of life of patients with a variety of immunodeficiency diseases such as lymphocytopenia, which is a common clinical feature in COVID-19. Conclusion Through the current review, it was concluded that this passive immunization may promote the immunity to better fight against the virus, so the survival of the patients could be kept longer. The efficacy of immunotherapy with IVIg would be greater if the immune IgG antibodies were collected from convalescent plasma therapy.

Sign in / Sign up

Export Citation Format

Share Document